Robert F. Siliciano

Robert F. Siliciano

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Robert F. Siliciano

Department of Medicine, Johns Hopkins University School of Medicine

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Cell
Verified
Journal Article
Closed access
YHYa-Chi Ho
Ya-Chi Ho
LSLiang Shan
Liang Shan
NHNina N. Hosmane
Nina N. Hosmane
JWJeffrey Wang
Jeffrey Wang
SLSarah B. Laskey
Sarah B. Laskey
RSRobert F. Siliciano
Robert F. Siliciano

8 August 2016 in Nature Medicine
Verified
Journal Article
Open access
PDF file
KBKatherine M Bruner
Katherine M Bruner
AMAlexandra J Murray
Alexandra J Murray
RPRoss A Pollack
Ross A Pollack
MSMary G Soliman
Mary G Soliman
SLSarah B Laskey
Sarah B Laskey
RSRobert F Siliciano
Robert F Siliciano
Bruner et al. report that defective HIV-1 proviruses predominate in early infection, even when antiretroviral therapy is initiated in the first months after infection. The results highlight challenges in estimating the reservoir of intact, replication-competent virus that may influence cure strategies. Although antiretroviral therapy (ART) suppresses viral replication to clinically undetectable levels, human immunodeficiency virus type 1 (HIV-1) persists in CD4+ T cells in a latent form that is not targeted by the immune system or by ART1,2,3,4,5. This latent reservoir is a major barrier to curing individuals of HIV-1 infection. Many individuals initiate ART during chronic infection, and in this setting, most proviruses are defective6. However, the dynamics of the accumulation and the persistence of defective proviruses during acute HIV-1 infection are largely unknown. Here we show that defective proviruses accumulate rapidly within the first few weeks of infection to make up over 93% of all proviruses, regardless of how early ART is initiated. By using an unbiased method to amplify near-full-length proviral genomes from HIV-1-infected adults treated at different stages of infection, we demonstrate that early initiation of ART limits the size of the reservoir but does not profoundly affect the proviral landscape. This analysis allows us to revise our understanding of the composition of proviral populations and estimate the true reservoir size in individuals who were treated early versus late in infection. Additionally, we demonstrate that common assays for measuring the reservoir do not correlate with reservoir size, as determined by the number of genetically intact proviruses. These findings reveal hurdles that must be overcome to successfully analyze future HIV-1 cure strategies.

30 January 2019 in Nature
Verified
Journal Article
Closed access
PDF file
KBKatherine M. Bruner
Katherine M. Bruner
ZWZheng Wang
Zheng Wang
FSFrancesco R. Simonetti
Francesco R. Simonetti
ABAlexandra M. Bender
Alexandra M. Bender
KKKyungyoon J. Kwon
Kyungyoon J. Kwon
RSRobert F. Siliciano
Robert F. Siliciano

1 March 2012 in Immunity
Verified
Journal Article
Closed access
LSLiang Shan
Liang Shan
KDKai Deng
Kai Deng
NSNeeta S. Shroff
Neeta S. Shroff
CDChristine M. Durand
Christine M. Durand
SRS. Alireza. Rabi
S. Alireza. Rabi
RSRobert F. Siliciano
Robert F. Siliciano

1 September 2011 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Closed access
PDF file
RSRobert F. Siliciano
Robert F. Siliciano
WGWarner C. Greene
Warner C. Greene
HIV-1 can establish a state of latent infection at the level of individual T cells. Latently infected cells are rare in vivo and appear to arise when activated CD4+ T cells, the major targets cells for HIV-1, become infected and survive long enough to revert back to a resting memory state, which is nonpermissive for viral gene expression. Because latent virus resides in memory T cells, it persists indefinitely even in patients on potent antiretroviral therapy. This latent reservoir is recognized as a major barrier to curing HIV-1 infection. The molecular mechanisms of latency are complex and include the absence in resting CD4+ T cells of nuclear forms of key host transcription factors (e.g., NFκB and NFAT), the absence of Tat and associated host factors that promote efficient transcriptional elongation, epigenetic changes inhibiting HIV-1 gene expression, and transcriptional interference. The presence of a latent reservoir for HIV-1 helps explain the presence of very low levels of viremia in patients on antiretroviral therapy. These viruses are released from latently infected cells that have become activated and perhaps from other stable reservoirs but are blocked from additional rounds of replication by the drugs. Several approaches are under exploration for reactivating latent virus with the hope that this will allow elimination of the latent reservoir.

7 January 2015 in Nature
Verified
Journal Article
Open access
PDF file
KDKai Deng
Kai Deng
MPMihaela Pertea
Mihaela Pertea
ARAnthony Rongvaux
Anthony Rongvaux
LWLeyao Wang
Leyao Wang
CDChristine M. Durand
Christine M. Durand
RSRobert F. Siliciano
Robert F. Siliciano
Despite receiving antiretroviral therapy, most patients with HIV still have latent reservoirs of the virus; here, these reservoirs are shown to be dominated by viruses with cytotoxic T lymphocyte escape mutations, with potential implications for the development of therapeutic vaccines. Antiretroviral therapy does not cure HIV-1 infection: despite drug treatment, most patients still have latent reservoirs of the virus. This study of immune cells isolated from 30 HIV-1-infected patients who had been on antiretroviral therapy for at least two years and had maintained undetectable plasma HIV-1 RNA levels, shows that these viral reservoirs are dominated by viruses with cytotoxic T lymphocyte escape mutations. This finding implies that future directions in therapeutic vaccine design may need to focus on boosting broad cytotoxic T lymphocyte responses. Despite antiretroviral therapy (ART), human immunodeficiency virus (HIV)-1 persists in a stable latent reservoir1,2, primarily in resting memory CD4+ T cells3,4. This reservoir presents a major barrier to the cure of HIV-1 infection. To purge the reservoir, pharmacological reactivation of latent HIV-1 has been proposed5 and tested both in vitro and in vivo6,7,8. A key remaining question is whether virus-specific immune mechanisms, including cytotoxic T lymphocytes (CTLs), can clear infected cells in ART-treated patients after latency is reversed. Here we show that there is a striking all or none pattern for CTL escape mutations in HIV-1 Gag epitopes. Unless ART is started early, the vast majority (>98%) of latent viruses carry CTL escape mutations that render infected cells insensitive to CTLs directed at common epitopes. To solve this problem, we identified CTLs that could recognize epitopes from latent HIV-1 that were unmutated in every chronically infected patient tested. Upon stimulation, these CTLs eliminated target cells infected with autologous virus derived from the latent reservoir, both in vitro and in patient-derived humanized mice. The predominance of CTL-resistant viruses in the latent reservoir poses a major challenge to viral eradication. Our results demonstrate that chronically infected patients retain a broad-spectrum viral-specific CTL response and that appropriate boosting of this response may be required for the elimination of the latent reservoir.